Drug intelligence / Profile preview

gamma-aminobutyric acid + piroxicam

Development stage
Approved
Modality
Small Molecules
Administration
Oral
01

Overview

gamma-aminobutyric acid + piroxicam is a combination drug containing gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system, and piroxicam, a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Piroxicam works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever[1][2]. The addition of GABA may theoretically augment analgesia by modulating synaptic transmission, although the specific pharmacodynamic synergy of this combination is not well-documented in the available literature. The combination is indicated for the relief of pain and inflammation in chronic conditions such as rheumatoid arthritis and osteoarthritis[3]. This product is formulated as a kit for oral administration and is intended for once daily dosing.

Brand names
Therafeldamine
Other names
THERAFELDAMINE
02

Targets

GABRR (GABA-A receptor subunit rho)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on gamma-aminobutyric acid + piroxicam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gamma-aminobutyric acid + piroxicam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call